This review summarizes neurobiological and genetic findings in behavioural addictions, draws parallels with findings pertaining to substance use disorders, and offers suggestions for future research. Articles concerning brain function, neurotransmitter activity, and family history and (or) genetic findings for behavioural addictions involving gambling, Internet use, video game playing, shopping, kleptomania, and sexual activity were reviewed. Behavioural addictions involve dysfunction in several brain regions, particularly the frontal cortex and striatum. Findings from imaging studies incorporating cognitive tasks have arguably been more consistent than cue-induction studies. Early results suggest white and grey matter differences. Neurochemical findings suggest roles for dopaminergic and serotonergic systems, but results from clinical trials seem more equivocal. While limited, family history and genetic data support heritability for pathological gambling and that people with behavioural addictions are more likely to have a close family member with some form of psychopathology. Parallels exist between neurobiological and genetic and family history findings in substance and nonsubstance addictions, suggesting that compulsive engagement in these behaviours may constitute addictions. To date, findings are limited, particularly for shopping, kleptomania, and sexual behaviour. Genetic understandings are at an early stage. Future research directions are offered.
American Psychiatric Association (APA)Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): APA; 2000.
2.
FrascellaJPotenzaMNBrownLLShared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint?Ann NY Acad Sci. 2010;1187:294–315.
3.
HoldenC.‘Behavioral’ addictions: Do they exist?Science. 2001;294(5544):980–982.
4.
HoldenC.Behavioral addictions debut in proposed DSM-V. Science. 2010;327(5968):935.
5.
KarimRChaudhriP.Behavioral addictions: An overview. J Psychoactive Drugs. 2012;44(1):5–17.
6.
PotenzaMN. Should addictive disorders include non-substance-related conditions?Addiction. 2006;101:142–151.
7.
PotenzaMN. The neurobiology of pathological gambling and drug addiction: An overview and new findings. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3181–3189.
8.
NestlerEJ. Is there a common molecular pathway for addiction?Nat Neurosci. 2005;8(11):1445–1449.
9.
CrabbeJC. Consilience of rodent and human phenotypes relevant for alcohol dependence. Addict Biol. 2010;15(2):103–108. Editorial.
10.
LeemanRFHeiligMCunninghamCLEthanol consumption: How should we measure it? Achieving consilience between human and animal phenotypes. Addict Biol. 2010;15(2):109–124.
11.
PotenzaMN. The importance of animal models of decision making, gambling, and related behaviors: Implications for translational research in addiction. Neuropsychopharmacology. 2009;34(13):2623–2624.
12.
ZeebFDRobbinsTWWinstanleyCA. Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. Neuropsychopharmacology. 2009;34(10):2329–2343.
13.
ShafferHJ. Strange bedfellows: A critical view of pathological gambling and addiction. Addiction. 1999;94(10):1445–1448.
14.
GrantJPotenzaM.The Oxford handbook of impulse control disorders. New York (NY): Oxford University Press; 2012.
15.
LoboDSKennedyJL. Genetic aspects of pathological gambling: A complex disorder with shared genetic vulnerabilities. Addiction. 2009;104(9):1454–1465.
16.
PotenzaMNSteinbergMAMcLaughlinSDGender-related differences in the characteristics of problem gamblers using a gambling helpline. Am J Psychiatry. 2001;158(9):1500–1505.
17.
BrewerJAPotenzaMN. The neurobiology and genetics of impulse control disorders: Relationships to drug addictions. Biochem Pharmacol. 2008;75(1):63–75.
18.
LeemanRFPotenzaMN. Similarities and differences between pathological gambling and substance use disorders: A focus on impulsivity and compulsivity. Psychopharmacology. 2012;219(2):469–490.
19.
BarrotMOlivierJDPerrottiLICREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proc Natl Acad Sci U S A. 2002;99(17):11435–11440.
20.
AvenaNMHoebelBG. A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine. Neuroscience. 2003;122(1):17–20.
21.
AvenaNMHoebelBG. Amphetamine-sensitized rats show sugar-induced hyperactivity (cross-sensitization) and sugar hyperphagia. Pharmacol Biochem Behav. 2003;74(3):635–639.
22.
ChambersRATaylorJRPotenzaMN. Developmental neurocircuitry of motivation in adolescence: A critical period of addiction vulnerability. Am J Psychiatry. 2003;160(6):1041–1052.
23.
EverittBJRobbinsTW. Neural systems of reinforcement for drug addiction: From actions to habits to compulsion. Nat Neurosci. 2005;8(11):1481–1489.
24.
JentschJDTaylorJR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl). 1999;146(4):373–390.
25.
KoobGFVolkowND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–238.
26.
ArnstenAF. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: A rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17(Suppl 1):i6–i15.
27.
KendlerKSChenXNDickDRecent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nat Neurosci. 2012;15(2):181–189.
28.
PotenzaMNXianHShahKShared genetic contributions to pathological gambling and major depression in men. Arch Gen Psychiatry. 2005;62(9):1015–1021.
29.
SlutskeWSEisenSTrueWRCommon genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry. 2000;57(7):666–673.
30.
GiddensJLXianHScherrerJFShared genetic contributions to anxiety disorders and pathological gambling in a male population. J Affect Disord. 2011;132(3):406–412.
LeemanRFPotenzaMN. Impulse control disorders in Parkinson's disease: Clinical characteristics and implications. Neuropsychiatry (London). 2011;1(2):133–147.
33.
LeemanRFBillingsleyBEPotenzaMN. Impulse control disorders in Parkinson's disease: Background and update on prevention and management. Neurodegener Dis Manag. 2012;2(4):389–400.
34.
PotenzaMNSteinbergMASkudlarskiPGambling urges in pathological gambling: A functional magnetic resonance imaging study. Arch Gen Psychiatry. 2003;60(8):828–836.
35.
GoudriaanAEDe RuiterMBVan Den BrinkWBrain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: An fMRI study. Addict Biol. 2010;15(4):491–503.
36.
CrockfordDNGoodyearBEdwardsJCue-induced brain activity in pathological gamblers. Biol Psychiatry. 2005;58(10):787–795.
37.
PotenzaMNLeungHCBlumbergHPAn fMRI stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160(11):1990–1994.
38.
ReuterJRaedlerTRoseMPathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci. 2005;8(2):147–148.
39.
TanabeJThompsonLClausEPrefrontal cortex activity is reduced in gambling and nongambling substance users during decision-making. Hum Brain Mapp. 2007;28(12):1276–1286.
40.
BalodisIMKoberHWorhunskyPDDiminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry. 2012;71(8):749–757.
41.
MiedlSFFehrTMeyerGNeurobiological correlates of problem gambling in a quasi-realistic blackjack scenario as revealed by fMRI. Psychiatry Res. 2010;181(3):165–173.
42.
PowerYGoodyearBCrockfordD.Neural correlates of pathological gamblers preference for immediate rewards during the Iowa Gambling Task: An fMRI study. J Gambl Stud. 2012;28(4):623–636.
43.
PallantiSHaznedarMMHollanderEBasal ganglia activity in pathological gambling: A fluorodeoxyglucose–positron emission tomography study. Neuropsychobiology2010;62(2):132–138.
44.
LinnetJMollerAPetersonEInverse association between dopaminergic neurotransmission and Iowa Gambling Task performance in pathological gamblers and healthy controls. Scand J Psychol. 2011;52(1):28–34.
45.
LinnetJMollerAPetersonEDopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction. 2011;106(2):383–390.
46.
PotenzaMNWalderhaugEHenrySSerotonin 1B receptor imaging in pathological gambling. World J Biol Psychiatry. 2011 Sep 22; Epub ahead of print.
47.
De GreckMEnziBPröschUDecreased neuronal activity in reward circuitry of pathological gamblers during processing of personal relevant stimuli. Hum Brain Mapp. 2010;31(11):1802–1812.
48.
HabibRDM. Neurobehavioral evidence for the “near miss” effect in pathological gamblers. J Exp Anal Behav. 2010(93):313–328.
49.
Van HolstRJVeltmanDJBüchelCDistorted expectancy coding in problem gambling: Is the addictive in the anticipation?Biol Psychiatry. 2012;71(8):741–748.
50.
De RuiterMBVeltmanDJGoudriaanAEResponse perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology2009;34(4):1027–1038.
51.
de RuiterMBOosterlaanJVeltmanDJSimilar hyporesponsiveness of the dorsomedial prefrontal cortex in problem gamblers and heavy smokers during an inhibitory control task. Drug Alcohol Depend. 2012;121(1–2):81–89.
52.
Verdejo-GarciaALawrenceAJClarkL.Impulsivity as a vulnerability marker for substance-use disorders: Review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev. 2008;32(4):777–810.
53.
JoutsaJSaunavaaraJParkkolaRExtensive abnormality of brain white matter integrity in pathological gambling. Psychiatry Res. 2011;194(3):340–346.
54.
YipSWLacadieCXuJReduced genual corpus callosal white matter integrity in pathological gambling and its relationship to alcohol abuse or dependence. World J Biol Psychiatry. 2011 May 5; Epub ahead of print.
55.
BlumKSheridanPJWoodRCThe D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996;89(7):396–400.
56.
JoutsaJJohanssonJNiemeläSMesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage. 2012;60(4):1992–1999.
57.
ZackMPoulosCX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology. 2004;29(1):195–207.
58.
ZackMPoulosCX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology. 2007;32(8):1678–1686.
59.
TremblayA-MDesmondRCPoulosCXHaloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. Addict Biol. 2011;16(3):467–484.
60.
FongTKalechsteinABernhardBA double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89(3):298–303.
61.
McElroySLNelsonEWelgeJOlanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69(3):433–440.
62.
PallantiSBernardiSAllenASerotonin function in pathological gambling: Blunted growth hormone response to Sumatriptan. J Psychopharmacol. 2010;24(12):1802–1809.
63.
DecariaCMBegazTHollanderEH. Serotonergic and noradrenergic function in pathological gambling. CNS Spectr. 1998;3:38–45.
64.
MarazzitiDGoliaFPicchettiMDecreased density of the platelet serotonin transporter in pathological gamblers. Neuropsychobiology. 2008;57(1–2):38–43.
65.
NordinCEcklundhT.Altered CSF 5-HIAA disposition in pathological male gamblers. CNS Spectr. 1999;4:25–33.
66.
PallantiSBernardiSQuercioliLSerotonin dysfunction in pathological gamblers: Increased prolactin response to oral m-CPP versus placebo. CNS Spectr. 2006;11:956–964.
67.
BullockSAPotenzaMN. Pathological gambling: Neuropsychopharmacology and treatment. Curr Psychopharmacol. 2012;1:67–85.
68.
BlancoCPetkovaEIbanezAA pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1):9–15.
KimSWGrantJEAdsonDEA double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling disorder. J Clin Psychiatry. 2002;63:501–507.
71.
GrantJEKimSWPotenzaMNParoxetine treatment of pathological gambling: A multi-center randomized controlled trial. Biol Psychiatry. 2003;53(8):200s–200s.
72.
Saiz-RuizJBlancoCIbáñezASertraline treatment of pathological gambling: A pilot study. J Clin Psychiatry. 2005;66(1):28–33.
73.
GrantJEPotenzaMNHollanderEMulticenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303–312.
74.
GrantJEKimSWHartmanBK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69(5):783–789.
75.
GrantJEOdlaugBLPotenzaMNNalmefene in the treatment of pathological gambling: Multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2011;197(4):330–331.
76.
KimSWGrantJEAdsonDEDouble-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–921.
77.
ToneattoTBrandsBSelbyP.A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18:219–225.
78.
GrantJEKimSWOdlaugBL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study. Biol Psychiatry. 2007;62:652–657.
79.
GrantJEChamberlainSROdlaugBLMemantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: A pilot study. Psychopharmacology. 2010;212:603–612.
80.
RoyAAdinoffBRoehrichLPathological gambling. A psychobiological study. Arch Gen Psychiatry. 1988;45(4):369–373.
81.
RoyADe JongJLinnoilaM.Extraversion in pathological gamblers. Correlates with indexes of noradrenergic function. Arch Gen Psychiatry. 1989;46(8):679–681.
82.
MeyerGSchwertfegerJExtonMSNeuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology2004;29(10): 1272–1280.
83.
PallantiSBernardiSAllenANoradrenergic function in pathological gambling: Blunted growth hormone response to clonidine. J Psychopharmacol. 2010;24(6):847–853.
84.
SlutskeWSZhuGMeierMHGenetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry. 2010;67(6):624–630.
85.
BlancoCMyersJKendlerKS. Gambling, disordered gambling and their association with major depression and substance use: A web-based cohort and twin-sibling study. Psychol Med. 2012;42(03):497–508.
86.
ShahKREisenSAXianHGenetic studies of pathological gambling: A review of methodology and analyses of data from the Vietnam Era Twin Registry. J Gambl Stud. 2005;21(2):179–203.
87.
ComingsDEGade-AndavoluRGonzalezNThe additive effect of neurotransmitter genes in pathological gambling. Clin Genet. 2001;60(2):107–116.
88.
Da Silva LoboD SabbatiniValladaHKnightJDopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud. 2007;23(4):421–433.
89.
ComingsDERosenthalRJLesieurHRA study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics. 1996;6(3):223–234.
90.
ComingsDEGadeRWuSStudies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry. 1997;2(1):44–56.
91.
ComingsDEGonzalezNWuSStudies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999;88(4):358–368.
92.
De CastroI PérezIbáñezATorresPGenetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics. 1997;7(5):345–348.
93.
LimSHaJChoiS-WAssociation study on pathological gambling and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in a Korean population. J Gambl Stud. 2012;28(3):481–491.
94.
De CastroIPIbánezASaiz-RuizJGenetic contribution to pathological gambling: Possible association between a functional DNA polymorphism at the serotonin transporter gene (5-HTT) and affected men. Pharmacogenet Genomics. 1999;9(3):397–400.
95.
IbañezADe CastroI PerezFernandez-PiquerasJPathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. Mol Psychiatry. 2000;5(1):105–109.
96.
De CastroIPIbanezASaiz-RuizJConcurrent positive association between pathological gambling and functional DNA polymorphisms at the MAO-A and the 5-HT transporter genes. Mol Psychiatry. 2002;7:927–928.
97.
LiuJGaoXPOsundeIIncreased regional homogeneity in internet addiction disorder: A resting state functional magnetic resonance imaging study. Chin Med J (Engl). 2010;123(14):1904–1908.
98.
KimSHBaikSHParkCSReduced striatal dopamine D2 receptors in people with Internet addiction. Neuroreport. 2011;22(8):407–411.
99.
LinFZhouYDuYAbnormal white matter integrity in adolescents with internet addiction disorder: A tract-based spatial statistics study. PLoS One. 2012;7(1):e30253.
100.
ZhouYLinFCDuYSGray matter abnormalities in Internet addiction: A voxel-based morphometry study. Eur J Radiol. 2011;79(1):92–95.
101.
YuanKQinWWangGMicrostructure abnormalities in adolescents with internet addiction disorder. PLoS One. 2011;6(6):e20708.
102.
HouHJiaSHuSReduced striatal dopamine transporters in people with internet addiction disorder. J Biomed Biotechnol. 2012;2012:854524. doi: 10.1155/2012/854524. Epub 2012 Mar 13.
103.
LeeYSHanDHYangKCDepression like characteristics of 5HTTLPR polymorphism and temperament in excessive internet users. J Affect Disord. 2008;109(1–2):165–169.
104.
ParkHSKimSHBangSAAltered regional cerebral glucose metabolism in internet game overusers: A 18F-fluorodeoxyglucose positron emission tomography study. CNS Spectr. 2010;15(3):159–166.
105.
KoCHLiuGCHsiaoSBrain activities associated with gaming urge of online gaming addiction. J Psychiatr Res. 2009;43(7):739–747.
106.
KoCHLiuGCYenJYBrain correlates of craving for online gaming under cue exposure in subjects with Internet gaming addiction and in remitted subjects. Addict Biol. 2011 Oct 26; Epub ahead of print.
107.
HanDHKimYSLeeYSChanges in cue-induced, prefrontal cortex activity with video-game play. Cyberpsychol Behav Soc Netw. 2010;13(6):655–661.
108.
DongGHuangJDuX.Enhanced reward sensitivity and decreased loss sensitivity in Internet addicts: An fMRI study during a guessing task. J Psychiatr Res. 2011;45(11):1525–1529.
109.
HanDHLyooIKRenshawPF. Differential regional gray matter volumes in patients with on-line game addiction and professional gamers. J Psychiatr Res. 2012;46(4):507–515.
110.
HanDHLeeYSYangKCDopamine genes and reward dependence in adolescents with excessive internet video game play. J Addict Med. 2007;1(3):133–138.
111.
YoshimotoKMcBrideWJLumengLAlcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol. 1992;9(1):17–22.
112.
RaabGElgerCNeunerMA neurological study of compulsive buying behaviour. J Consum Policy. 2011;34(4):401–413.
113.
KnutsonBRickSWimmerGENeural predictors of purchases. Neuron. 2007;53(1):147–156.
114.
KoranLMBullockKDHartstonHJCitalopram treatment of compulsive shopping: An open-label study. J Clin Psychiatry. 2002;63(8):704–708.
115.
KoranLMChuongHWBullockKDCitalopram for compulsive shopping disorder: An open-label study followed by double-blind discontinuation. J Clin Psychiatry. 2003;64(7):793–798.
116.
BlackDWGabelJHansenJA double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry. 2000;12(4):205–211.
117.
NinanPTMcElroySLKaneCPPlacebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol. 2000;20(3):362–366.
118.
KoranLMAboujaoudeENSolvasonBEscitalopram for compulsive buying disorder: A double-blind discontinuation study. J Clin Psychopharmacol. 2007;27(2):225–227.
BlackDWRepertingerSGaffneyGRFamily history and psychiatric comorbidity in persons with compulsive buying: Preliminary findings. Am J Psychiatry. 1998;155(7):960–963.
121.
DevorEJMageeHJDill-DevorRMSerotonin transporter gene (5-HTT) polymorphisms and compulsive buying. Am J Med Genet. 1999;88(2):123–125.
122.
GrantJECorreiaSBrennan-KrohnT.White matter integrity in kleptomania: A pilot study. Psychiatry Res. 2006;147(2–3):233–237.
123.
GrantJEOdlaugBLKimSW. Kleptomania: Clinical characteristics and relationship to substance use disorders. Am J Drug Alcohol Abuse. 2010;36(5):291–295.
124.
MarazzitiDPrestaSPfannerCThe biological basis of kleptomania and compulsive buying. Scientific Abstracts, American College of Neuropsychopharmacology 39th Annual Meeting. San Juan, Puerto Rico: ACNP; 2000.
125.
KoranLMAboujaoudeENGamelNN. Escitalopram treatment of kleptomania: An open-label trial followed by double-blind discontinuation. J Clin Psychiatry. 2007;68(3):422–427.
126.
GrantJEKimSWOdlaugBL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009;65(7):600–606.
127.
GrantJEKimKW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry. 2002;43(5):378–384.
128.
McElroySLHudsonJIPopeHThe DSM-III-R impulse control disorders not elsewhere classified: Clinical characteristics and relationship to other psychiatric disorders. Am J Psychiatry. 1992;149(3):318–327.
129.
MinerMHRaymondNMuellerBAPreliminary investigation of the impulsive and neuroanatomical characteristics of compulsive sexual behavior. Psychiatry Res. 2009;174(2):146–151.
130.
WainbergMLMuenchFMorgensternJA double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry. 2006;67(12):1968–1973.
131.
SchneiderJPSchneiderBH. Couple recovery from sexual addiction: Research findings of a survey of 88 marriages. Sex Addict Compulsivity1996;3:111–126.
132.
McQueenyTSchweinsburgBCSchweinsburgADAltered white matter integrity in adolescent binge drinkers. Alcohol Clin Exp Res. 2009;33(7):1278–1285.
133.
PfefferbaumASullivanEVHedehusMIn vivo detection and functional correlates of white matter microstructural disruption in chronic alcoholism. Alcohol Clin Exp Res. 2000;24(8):1214–1221.
134.
GoldsteinRZAlia-KleinNTomasiDIs decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction?Am J Psychiatry. 2007;164(1):43–51.
135.
GoldsteinRZTomasiDRajaramSRole of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction. Neuroscience. 2007;144(4):1153–1159.
136.
PotenzaMNLeungH-CBlumbergHPAn fMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160(11):1990–1994.
137.
BeckASchlagenhaufFWüstenbergTVentral striatal activation during reward anticipation correlates with impulsivity in alcoholics. Biol Psychiatry. 2009;66(8):734–742.
138.
HommerDBjorkJKnutsonBMotivation in children of alcoholics. Alcohol Clin Exp Res. 2004;28:22A.
139.
PetersJBrombergUSchneiderSLower ventral striatal activation during reward anticipation in adolescent smokers. Am J Psychiatry. 2011;168:540–549.
140.
WraseJSchlagenhaufFKienastTDysfunction of reward processing correlates with alcohol craving in detoxified alcoholics. Neuroimage. 2007;35(2):787–794.
141.
JiaZWorhunskyPDCarrollKMAn initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. Biol Psychiatry. 2011;70(6):553–560.
142.
NestorLHesterRGaravanH.Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage. 2010;49(1):1133–1143.
143.
VolkowNDWangG-JTelangFCocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583–6588.
144.
Vollstädt-KleinSWichertSRabinsteinJInitial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction. 2010;105(10):1741–1749.
145.
ShiJZhaoLYCopersinoMLPET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol. 2008;579(1–3):160–166.
146.
VolkowNDFowlerJSWangG-J.The addicted human brain: Insights from imaging studies. J Clin Invest. 2003;111(10):1444–1451.
147.
SchlaepferTEPearlsonGDWongDFPET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Am J Psychiatry. 1997;154(9):1209–1213.
148.
RitzMLambRGoldbergCocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237(4819):1219–1223.
149.
Crits-ChristophPNewbergAWinteringNDopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend. 2008;98(1–2):70–76.
150.
VolkowND. Opioid–dopamine interactions: Implications for substance use disorders and their treatment. Biol Psychiatry. 2010;68(8):685.
151.
Fils-AimeMLEckardtMJGeorgeDTEarly-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry. 1996;53(3):211–216.
152.
RatsmaJEVan Der SteltOGunningWB. Neurochemical markers of alcoholism vulnerability in humans. Alcohol Alcohol. 2002;37(6):522–533.
153.
CoiroVVescoviPP. Persistence of defective serotonergic and GABAergic controls of growth hormone secretion in long-term abstinent alcoholics. Alcohol Alcohol. 1997;32(1):85–90.
154.
BenderSScherbaumNSoykaMThe efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: A randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int J Neuropsychopharmacol. 2007;10(5):653–660.
155.
KampmanKMPettinatiHLynchKGA pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70(3):265–273.
156.
ShawGKWallerSMajumdarSKTiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry. 1994;165(4):515–523.
157.
AmatoLMinozziSPaniPPAntipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2007(3):CD006306.
158.
GuardiaJSeguraLGonzalvoBA double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28(5):736–745.
159.
TorrensMFonsecaFMateuGEfficacy of antidepressants in substance use disorders with and without comorbid depression: A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1–22.
160.
LobmaierPKornørHKunøeNSustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD006140.
RösnerSHackl-HerrwerthALeuchtSOpioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.
163.
LaroweSDMardikianPMalcolmRSafety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15(1):105–110.
164.
KrupitskyEMNeznanovaOMasalovDEffect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry. 2007;164(3):519–523.
165.
JobesMGhitzaUEpsteinDClonidine blocks stress-induced craving in cocaine users. Psychopharmacology. 2011;218(1):83–88.
166.
ShahamYErbSStewartJ.Stress-induced relapse to heroin and cocaine seeking in rats: A review. Brain Res Rev. 2000;33(1):13–33.
167.
SinhaRKimmerlingADoebrickCEffects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: Preliminary findings. Psychopharmacology. 2007;190(4):569–574.
168.
KreekMJNielsenDAButelmanERGenetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci. 2005;8(11):1450–1457.
169.
HanDHHwangJWRenshawPF. Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction. Exp Clin Psychopharmacol. 2010;18(4):297–304.
170.
KiltsCDSchweitzerJBQuinnCKNeural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001;58(4):334–341.
171.
DomGSabbeBHulstijnWSubstance use disorders and the orbitofrontal cortex: Systematic review of behavioural decision-making and neuroimaging studies. Br J Psychiatry. 2005;187:209–220.
172.
WilsonSJSayetteMAFiezJA. Prefrontal responses to drug cues: A neurocognitive analysis. Nat Neurosci. 2004;7(3):211–214.
173.
VolkowNDFowlerJSWangGJDopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol. 2007;64(11):1575–1579.
174.
MiedlSFPetersJBuchelC.Altered neural reward representations in pathological gamblers revealed by delay and probability discounting. Arch Gen Psychiatry. 2012;69(2):177–186.
